-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN) Drug Details: Cevira (APL-1702) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Arsenic Trioxide in Myelodysplastic Syndrome Drug Details:Arsenic trioxide is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN) Drug Details: Cevira (APL-1702) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Chronic Myelomonocytic Leukemia (CMML)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Arsenic Trioxide in Chronic Myelomonocytic Leukemia (CMML) Drug Details:Arsenic trioxide is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Myeloproliferative Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Arsenic Trioxide in Myeloproliferative Disorders Drug Details:Arsenic trioxide is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Solid Tumor Drug Details: APL-101 (CBT-101) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Omacetaxine Mepesuccinate in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Omacetaxine Mepesuccinate in Relapsed Acute Myeloid Leukemia Drug Details:Omacetaxine mepesuccinate (Homoharringtonine, Omapro, Synribo, Tekinex, CGX635) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Omacetaxine Mepesuccinate in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Omacetaxine Mepesuccinate in Refractory Acute Myeloid Leukemia Drug Details:Omacetaxine mepesuccinate (Homoharringtonine, Omapro, Synribo, Tekinex, CGX635) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Renal Cell Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Renal Cell Carcinoma Drug Details: APL-101 (CBT-101) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Omacetaxine Mepesuccinate in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Omacetaxine Mepesuccinate in Myelodysplastic Syndrome Drug Details:Omacetaxine mepesuccinate (Homoharringtonine, Omapro, Synribo, Tekinex, CGX635) is an antineoplastic agent....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.